These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36862400)

  • 1. Is Anti-Vascular Growth Factor Therapy for Retinopathy of Prematurity Associated With Pulmonary Hypertension?-Reply.
    Nitkin CR; Richardson T; Lewis T
    JAMA Ophthalmol; 2023 Apr; 141(4):408-409. PubMed ID: 36862400
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Anti-Vascular Growth Factor Therapy for Retinopathy of Prematurity Associated With Pulmonary Hypertension?
    Kumar VHS
    JAMA Ophthalmol; 2023 Apr; 141(4):407-408. PubMed ID: 36862405
    [No Abstract]   [Full Text] [Related]  

  • 3. Is Anti-Vascular Growth Factor Therapy for Retinopathy of Prematurity Associated With Pulmonary Hypertension?
    Raghuveer TS; Zackula RE; Okut H
    JAMA Ophthalmol; 2023 Apr; 141(4):406-407. PubMed ID: 36862404
    [No Abstract]   [Full Text] [Related]  

  • 4. Is Anti-Vascular Growth Factor Therapy for Retinopathy of Prematurity Associated With Pulmonary Hypertension?
    Chiang PH; Lin CC
    JAMA Ophthalmol; 2023 Apr; 141(4):407. PubMed ID: 36862391
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension.
    Park L; Donohue L; Lakshminrusimha S; Sankaran D
    J Perinatol; 2023 Feb; 43(2):236-237. PubMed ID: 35970854
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary Hypertension and Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity-Is There a Link?
    Patel SN
    JAMA Ophthalmol; 2022 Nov; 140(11):1094-1095. PubMed ID: 36201187
    [No Abstract]   [Full Text] [Related]  

  • 7. Fundus Pigmentation in the Diagnosis and Treatment of Retinopathy of Prematurity.
    Fan KC; Read SP; Patel NA; Vanner EA; Al-Khersan H; Laura DM; Pakravan P; Negron CI; Berrocal AM
    Ophthalmology; 2021 Aug; 128(8):1242-1244. PubMed ID: 33383092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of aggressive posterior retinopathy of prematurity in oculocutaneous albinism.
    Panchal B; Gulati M
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 10. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
    Vinekar A
    Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
    [No Abstract]   [Full Text] [Related]  

  • 11. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity.
    Chen X; Imperio R; Seely KR; Viehland C; Izatt JA; Prakalapakorn SG; Freedman SF; Toth CA
    J AAPOS; 2020 Oct; 24(5):323-326. PubMed ID: 33045380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for retinopathy of prematurity and neurodevelopment.
    Wallace DK;
    J AAPOS; 2024 Feb; 28(1):103786. PubMed ID: 37926389
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab for retinopathy of prematurity and neurodevelopment.
    Binenbaum G
    J AAPOS; 2023 Feb; 27(1):1-2. PubMed ID: 36623638
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series].
    Martínez-García SM; Hernández-Da Mota SE; Rubio-Rangel A; Rojas-Flores I; Vieyra-López ME; Martínez-Castellanos MA; Zavala-Martínez MT; Gómez García A
    Cir Cir; 2017; 85(6):478-484. PubMed ID: 28110900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Low-dose Intravitreal Bevacizumab and Ranibizumab on Regression and Late Reactivation in Retinopathy of Prematurity in the Treatment-Naïve Eyes.
    Zhang C; Reynolds AL; Beiter A; Lillvis JH; Reynolds JD
    Ophthalmol Retina; 2022 Apr; 6(4):328-330. PubMed ID: 34968757
    [No Abstract]   [Full Text] [Related]  

  • 19. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor.
    Hartnett ME
    Am J Ophthalmol; 2020 Oct; 218():208-213. PubMed ID: 32450064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Levels of Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity Study-More Questions Than Answers?-Reply.
    Hartnett ME; Wallace DK
    JAMA Ophthalmol; 2022 Sep; 140(9):911-912. PubMed ID: 35925587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.